According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.6257. At the end of 2022 the company had a P/E ratio of 19.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 19.4 | 78.04% |
2021 | 10.9 | -3.03% |
2020 | 11.2 | -33.04% |
2019 | 16.8 | 8.69% |
2018 | 15.4 | -11.69% |
2017 | 17.5 | -13.01% |
2016 | 20.1 | 39.08% |
2015 | 14.5 | -17.42% |
2014 | 17.5 | 83.14% |
2013 | 9.56 | -42.74% |
2012 | 16.7 | 20.2% |
2011 | 13.9 | 5% |
2010 | 13.2 | -14.34% |
2009 | 15.4 | -11.05% |
2008 | 17.4 | -41.91% |
2007 | 29.9 | 68.04% |
2006 | 17.8 | -6.38% |
2005 | 19.0 | -2.38% |
2004 | 19.5 | 12.33% |
2003 | 17.3 | 1.39% |
2002 | 17.1 | -58.3% |
2001 | 41.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
LabCorp LH | 26.5 | 42.40% | ๐บ๐ธ USA |
Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
Psychemedics PMD | -7.51 | -140.29% | ๐บ๐ธ USA |
NeoGenomics
NEO | -15.0 | -180.36% | ๐บ๐ธ USA |
Qiagen QGEN | 27.1 | 45.72% | ๐ณ๐ฑ Netherlands |
Enzo Biochem ENZ | -1.20 | -106.45% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.